ArticleJournal of biological engineering2026
Pathway reconstruction of Corynebacterium glutamicum for C30 carotenoid 4,4'-diaponeurosporene production.
Article in Journal of biological engineering, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
4,4′-Diaponeurosporene (4,4′-DIA) is a rare C30 carotenoid with strong antioxidant and immune-enhancing properties. However, microbial production of 4,4′-DIA has been limited by low titers and the simultaneous formation of undesired carotenoid byproducts. In this study, Corynebacterium glutamicum was rationally engineered to enable selective 4,4′-DIA biosynthesis through pathway reconstruction. To redirect metabolic flux toward C30 carotenoids, the native C50 carotenoid biosynthetic gene cluster was deleted and the precursor supply was reconfigured by replacing the core C20 derivative pathway with ispA to produce C15 precursor. A gene module enabling high-level and selective production of 4,4′-DIA was established through the combinatorial expression of crtM and crtN in a constitutive vector system. Pathway analysis predicted crtN to be a bottleneck in 4,4′-DIA biosynthesis, and its expression was strengthened through promoter introduction, leading to improved production level. Deletion of poxB and ldhA combined with ribK overexpression enhanced both 4,4′-DIA biosynthetic gene expression and production, likely due to improvement carbon flux and cofactor supply. The final engineered strain was successfully transferred to a 5-L fed-batch fermentation with a 4,4′-DIA titer of 656.3 mg/L without any inducer. This work demonstrates the selective production of the rare and non-commercial C30 carotenoid 4,4′-DIA in C. glutamicum, establishing it as a robust platform for diversified carotenoid biosynthesis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.